Quantcast

Posts Tagged: biotech patents


In a least one instance a major laboratory test provider has indicated in confidence that it would not be entering the Ebola testing market for three principle reasons the lack of availability of exclusivity for genetic testing the liability…

Continue Reading

A look into the recently published patent applications assigned to Dow from the U S Patent and Trademark Organization shows us that GMOs and herbicides have been a major area of focus for Dow and Dow AgroSciences its chief…

Continue Reading

On the very same day that the U S jobs report shows unexpectedly weak growth the Federal Court of Australia issued a ruling directly opposite to the ruling rendered by the United States Supreme Court relative to gene patents…

Continue Reading

Although complementary patents and data exclusivity protection incentivize innovation in different ways and serve distinct purposes Patents provide protection for innovations that meet the standards of patentability and are novel nonobvious and useful In the context of biopharmaceuticals patents…

Continue Reading

Written by David J Kappos former Director of the USPTO The language of the Myriad decision did not on its face mandate drastic innovation-dampening action The Supreme Court chose to narrowly decide the Myriad case stating that a DNA…

Continue Reading

On the method claims the test derived from Prometheus is whether the claims add enough to a natural principle law of nature natural phenomenon to make them go beyond claiming just the natural principle law of natural natural phenomenon…

Continue Reading

Today after several years of substantial turmoil patent eligibility in a variety of economically significant technologies is extremely uncertain including software natural products medical diagnostics and personalized medicine It is with great irony that one of the few things…

Continue Reading

In order to fabricate a case or controversy where clearly none existed the farmers AFTER filing the declaratory judgment action sent Monsanto a letter which asked Monsanto to expressly waive any claim for patent infringement they may ever have…

Continue Reading

You can expect a near complete cessation in many areas of personalized medicine If creating something in a lab such as a composite cDNA does not make the underlying claims patent eligible because what results is indistinguishable from what…

Continue Reading

Some had hoped that the Court would use Bowman as an opportunity to address the extent of a patent owner s monopoly over other self-replicating technologies in the areas of biotechnology and information technology such as human cell lines…

Continue Reading

Social policy concerns have influenced the AMP v Myriad debate The Supreme Court to the extent it must make a ruling for our times informed by societal context should dispassionately consider all the available empirical evidence from the academic…

Continue Reading

As the patent community waits to see whether the United States Supreme Court will deal a significant perhaps fatal blow to the patenting of many genetic related innovations in Association of Molecular Pathology v Myriad Genetics announcement came this…

Continue Reading